期刊
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV
卷 24, 期 12, 页码 1504-1513出版社
ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
DOI: 10.1080/09540121.2012.672718
关键词
HIV/AIDS; cognition; medication adherence; antiretroviral; methamphetamine
类别
资金
- NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH062512] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON DRUG ABUSE [T32DA031098, P01DA012065, P50DA026306] Funding Source: NIH RePORTER
- NIDA NIH HHS [P01DA012065, P50 DA026306, T32 DA031098, P50DA026306, P01 DA012065, T32DA31098] Funding Source: Medline
- NIMH NIH HHS [P30MH62512, P30 MH062512, MH 62512] Funding Source: Medline
The present study assesses the impact of methamphetamine (METH) on antiretroviral therapy (ART) adherence among HIV + persons, as well as examines the contribution of neurocognitive impairment and other neuropsychiatric factors [i.e., major depressive disorder (MDD), antisocial personality disorder (ASPD), and attention deficit disorder (ADHD)] for ART non-adherence. We examined HIV + persons with DSM-IV-diagnosed lifetime history of METH abuse/dependence (HIV + /METH +; n = 67) as compared to HIV + participants with no history of METH abuse/dependence (HIV + /METH +; n = 50). Ancillary analyses compared these groups with a small group of HIV + /METH + persons with current METH abuse/dependence (HIV + /CU METH +; n = 8). Non-adherence was defined as self-report of any skipped ART dose in the last four days. Neurocognitive functioning was assessed with a comprehensive battery, covering seven neuropsychological domains. Lifetime METH diagnosis was associated with higher rates of detectable levels of plasma and CSF HIV RNA. When combing groups (i. e., METH + and METH + participants), univariate analyses indicated co-occurring ADHD, ASPD, and MDD predicted ART non-adherence (p's<0.10; not lifetime METH status or neurocognitive impairment). A significant multivariable model including these variables indicated that only MDD uniquely predicted ART non-adherence after controlling for the other variables (p<0.05). Ancillary analyses indicated that current METH users (use within 30 days) were significantly less adherent (50% prevalence of non-adherence) than lifetime METH + users and HIV + /METH + participants and that neurocognitive impairment was associated with non-adherence (p's<0.05). METH use disorders are associated with worse HIV disease outcomes and ART medication non-adherence. Interventions often target substance use behaviors alone to enhance antiretroviral treatment outcomes; however, in addition to targeting substance use behaviors, interventions to improve ART adherence may also need to address coexisting neuropsychiatric factors and cognitive impairment to improve ART medication taking.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据